ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative therapies that combine efficacy, safety, and broad clinical applicability.
ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.
ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.
COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

COMy 2026 | Professor Nizar Bahlis: A Comprehensive Framework for Understanding and Overcoming Bispecific Antibody Resistance in Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential global meetings in the field of multiple myeloma (MM), the congress brought together leading investigators to discuss the latest advances in translational research, innovative therapies, and patient care.
COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

COMy 2026 | Professor Philippe Moreau: Thirty-Five Years of Progress—Tracing the Evolution of Frontline Therapy for Transplant-Eligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential meetings in the field of multiple myeloma (MM), the congress brought together leading experts to discuss the latest advances in research, innovative therapies, and patient care.